## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (1.5%) confirms momentum alignment. Strong momentum (+5.3% 5-day acceleration). Outperforming sector by 7.3%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($33.05)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Norges Bank Invests $35.77 Million in Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251208T110921 | Somewhat-Bullish | Relevance: 98%
-  Norges Bank acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, purchasing 983,638 shares valued at approximately $35.77 million. This investment makes Norges Bank an owner of about 1.02% of the biopharmaceutical company. Other institutional investors also adjusted their holdings in Ultragenyx Pharmaceutical, with several increasing their stakes.

**2. Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up - Time to Buy?**
- Source: MarketBeat | 20251208T180951 | Neutral | Relevance: 97%
-  Ultragenyx Pharmaceutical (NASDAQ:RARE) shares gapped up pre-market, opening at $39.00 from a previous close of $36.38, and last traded around $37.34. Despite an analyst consensus of "Moderate Buy" with an average price target of $80.23, several firms recently trimmed their targets. The company recently missed quarterly EPS and revenue estimates, reporting a negative net margin.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (8.4%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +5.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 0.16 |
| 52W Range | $25.81 - $50.00 |
| Short Interest | 8.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -1.3% to 3.9% (+5.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 1.5% confirms short-term momentum alignment. Outperforming sector by 7.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.94% (CS: 87) | Strong |
| RSI_14 | 63.0 | Neutral |
| MACD Histogram | 0.37 | Bullish |
| vs SMA20 | 1.081x | Above |
| vs SMA50 | 1.107x | Above |
| vs SMA200 | 1.076x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $36.45
- **Stop Loss:** $33.05 (9.3% risk)
- **Target:** $41.55 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 147
- **Position Value:** $5,358.15
- **Portfolio %:** 5.36%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*